Hasil Pencarian - Edward B Garon

Perbaiki Hasil
  1. 1
    The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?

    The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? oleh Amy L. Cummings, Edward B. Garon

    Diterbitkan 2017-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

    Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review oleh Edward B. Garon, Carla Visseren-Grul, Maria Teresa Rizzo, Tarun Puri, Suresh Chenji, Martin Reck

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    The Role of Interleukin 1β in the Pathogenesis of Lung Cancer

    The Role of Interleukin 1β in the Pathogenesis of Lung Cancer oleh Edward B. Garon, MD, James Chih-Hsin Yang, MD, PhD, Steven M. Dubinett, MD

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

    Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review oleh Philippe Rochigneux, Philippe Rochigneux, Philippe Rochigneux, Alejandro J. Garcia, Brice Chanez, Anne Madroszyk, Daniel Olive, Edward B. Garon

    Diterbitkan 2020-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

    Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients oleh Haiyan E. Liu, Meghah Vuppalapaty, Charles Wilkerson, Corinne Renier, Michael Chiu, Clementine Lemaire, James Che, Melissa Matsumoto, James Carroll, Steve Crouse, Violet R. Hanft, Stefanie S. Jeffrey, Dino Di Carlo, Dino Di Carlo, Dino Di Carlo, Edward B. Garon, Edward B. Garon, Jonathan Goldman, Jonathan Goldman, Elodie Sollier

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

    Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis oleh Shuo Li, Zorawar S. Noor, Weihua Zeng, Mary L. Stackpole, Xiaohui Ni, Yonggang Zhou, Zuyang Yuan, Wing Hung Wong, Vatche G. Agopian, Steven M. Dubinett, Frank Alber, Wenyuan Li, Edward B. Garon, Xianghong Jasmine Zhou

    Diterbitkan 2021-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC

    Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC oleh Puja Shahrouki, MD, Jay M. Lee, MD, Jonathan Barclay, MD, Sarah N. Khan, MD, Scott Genshaft, MD, Fereidoun Abtin, MD, Steven M. Dubinett, MD, Aaron Lisberg, MD, Sherven Sharma, PhD, Edward B. Garon, MD, Robert Suh, MD

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

    RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants oleh Kazumi Nishino, MD, PhD, Jin-Yuan Shih, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Michelle Carlsen, MS, Tomoko Matsui, Carla Visseren-Grul, MD, Ernest Nadal, MD, PhD

    Diterbitkan 2024-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib

    Brief Report: Severe Pneumonitis After Combined Thoracic Radiotherapy and Osimertinib oleh Clayton P. Smith, MD, Michael Xiang, MD, PhD, Stephanie M. Yoon, MD, Alan Lee, MD, Dan Ruan, PhD, Jonathan W. Goldman, MD, Amy L. Cummings, MD, Aaron Lisberg, MD, Edward B. Garon, MD, MS, Drew Moghanaki, MD, MPH

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

    Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists oleh Kathryn F. Mileham, Caroline Schenkel, Suanna S. Bruinooge, Janet Freeman‐Daily, Upal Basu Roy, Amy Moore, Robert A. Smith, Elizabeth Garrett‐Mayer, Lauren Rosenthal, Edward B. Garon, Bruce E. Johnson, Raymond U. Osarogiagbon, Shadia Jalal, Shamsuddin Virani, Mary Weber Redman, Gerard A. Silvestri

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities

    Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities oleh Ariane Lozac’hmeur, Tyler Danek, Qidi Yang, Mario G. Rosasco, John S. Welch, William Y. Go, Eric W. Ng, Armen Mardiros, David G. Maloney, Edward B. Garon, Kedar Kirtane, Diane M. Simeone, Julian R. Molina, Ameen A. Salahudeen, Michelle M. Stein, J. Randolph Hecht

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

    CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity oleh Bin Liu, Rui Li, Edward B Garon, Steven M Dubinett, Kostyantyn Krysan, Tianhao Zhang, Aaron E Lisberg, Ramin Salehi-Rad, Raymond J Lim, Yushen Du, Linh M Tran, Stephanie L Ong, Zi Ling Huang, Camelia Dumitras, Stacy J Park, William Crosson, Bitta Kahangi, Jensen Abascal, Christopher Seet, Michael Oh, Maryam Shabihkhani, Manash Paul

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

    The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) oleh Julie R. Brahmer, Ramaswamy Govindan, Robert A. Anders, Scott J. Antonia, Sarah Sagorsky, Marianne J. Davies, Steven M. Dubinett, Andrea Ferris, Leena Gandhi, Edward B. Garon, Matthew D. Hellmann, Fred R. Hirsch, Shakuntala Malik, Joel W. Neal, Vassiliki A. Papadimitrakopoulou, David L. Rimm, Lawrence H. Schwartz, Boris Sepesi, Beow Yong Yeap, Naiyer A. Rizvi, Roy S. Herbst

    Diterbitkan 2018-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

    Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma oleh Raffit Hassan, Patrick M Forde, Edward B Garon, Steven M Dubinett, Roy S Herbst, Charu Aggarwal, Matthew D Hellmann, Sarah B Goldberg, David L Rimm, Sarah Sagorsky, Boris Sepesi, Ramaswamy Govindan, Andrea Ferris, Scott J Antonia, Fred R Hirsch, Lawrence H Schwartz, Marianne Davies, Melissa L Johnson, Shakun Malik, Daniel Morgensztern, Joel W Neal, Jyoti D Patel

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status

    364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status oleh Enriqueta Felip, Marina Chiara Garassino, Edward B Garon, Roy S Herbst, Razvan Cristescu, Martin Reck, Yi-Long Wu, Byoung Chul Cho, Michael Boyer, Delvys Rodriguez-Abreu, Hidehito Horinouchi, Rina Hui, Gilberto de Castro, Gilberto Lopes, Dariusz M Kowalski, Hande Z Turna, Tony SK Mok, Shirish M Gadgeel, Kazuo Kasahara, Julie Kobie, Yongjin Li, Mark A Ayers, M Catherine Pietanza

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC

    Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC oleh Patricia A. Young, MD, Diana C. Márquez-Garbán, MD, Zorawar Singh Noor, MD, Neda Moatamed, MD, David Elashoff, PhD, Tristan Grogan, PhD, Tahmineh Romero, PhD, Hironobu Sasano, MD, PhD, Ryoko Saito, MD, PhD, Rebecca Rausch, PhD, Nalo Hamilton, PhD, Steven M. Dubinett, MD, Edward B. Garon, MD, Richard J. Pietras, MD, PhD

    Diterbitkan 2021-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC

    RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC oleh Makoto Nishio, MD, PhD, Kazuto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, Fumio Imamura, MD, PhD, Tomoya Kawaguchi, PhD, Hiroyuki Yamaguchi, MD, PhD, Satoshi Ikeda, MD, PhD, Katsuya Hirano, MD, Carla Visseren-Grul, MD, Matteo Ceccarelli, PharmD, MS, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Tomoko Matsui, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042

    Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042 oleh Aaron S. Mansfield, MD, Roy S. Herbst, MD, PhD, Gilberto de Castro, Jr., MD, PhD, Rina Hui, MB, BS, PhD, Nir Peled, MD, PhD, Dong-Wan Kim, MD, Silvia Novello, MD, PhD, Miyako Satouchi, MD, Yi-Long Wu, MD, Edward B. Garon, MD, Martin Reck, MD, PhD, Andrew G. Robinson, MD, Ayman Samkari, MD, Bilal Piperdi, MD, Victoria Ebiana, MD, Jianxin Lin, MS, Tony S.K. Mok, MD

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Proceedings of the 2016 China Cancer Immunotherapy Workshop

    Proceedings of the 2016 China Cancer Immunotherapy Workshop oleh Bin Xue, Jiaqi Xu, Wenru Song, Zhimin Yang, Ke Liu, Zihai Li, Zihai Li, Lieping Chen, Edward B. Garon, Siwen Hu-Lieskovan, Wei Ding, Chong-Xian Pan, Weijing Sun, Yong-Jun Liu, Lei Zheng, Delong Liu, Michel Sadelain, Cassian Yee, Rongfu Wang, Meixia Chen, Yao Wang, Zhiqiang Wu, Hanren Dai, Can Luo, Yang Liu, Chuan Tong, Yelei Guo, Qingming Yang, Weidong Han, Lisa H. Butterfield, Timothy A. Chan, Wenru Song, Ruirong Yuan, Bo Lu, Ke Liu, Max Ning, Harald Enzmann, Heinz Zwierzina

    Diterbitkan 2016-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC oleh Marina C. Garassino, MD, Shirish Gadgeel, MD, Silvia Novello, MD, PhD, Balazs Halmos, MD, Enriqueta Felip, MD, Giovanna Speranza, MD, Rina Hui, PhD, Edward B. Garon, MD, Hidehito Horinouchi, MD, PhD, Shunichi Sugawara, MD, PhD, Delvys Rodriguez-Abreu, MD, PhD, Martin Reck, MD, Razvan Cristescu, PhD, Deepti Aurora-Garg, PhD, Andrey Loboda, PhD, Jared Lunceford, PhD, Julie Kobie, PhD, Mark Ayers, MS, Bilal Piperdi, MD, M. Catherine Pietanza, MD, Luis Paz-Ares, MD, PhD

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: